**Table 1:** Clinical and Laboratory Characteristics of Patients with/without AF (n = 23).

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Sinus Rhythm** | **Atrial Fibrillation** | ***P* Value** |
|
|
| Number of visits in the 4-year follow-up period | 28 | 33 | - |
| Age (y) | 76.1 ± 5.5 | 74.0 ± 6.1 | 0.079 |
| Men/women (%) | 57/43 | 57/43 | 0.37 |
| Body mass index | 29.0 ± 6.8 | 29.3 ± 7.5 | 0.442 |
| Diabetes mellitus (%) | 32.10% | 18.20% | 0.34 |
| Coronary artery disease (%) | 7.1 | 9 | 0.784 |
| Heart failure (%) | 0 | 0 | 1 |
| Smoking (%) | 3 | 3 | 0.358 |
|  |  |  |  |
| **Antihypertensives** |  |  |  |
| CCB (%) | 25 | 7.1 | 0.025 |
| BB (%) | 64.3 | 45.5 | 0.598 |
| ACEi (%) | 35.7 | 33.3 | 0.847 |
| ARB (%) | 28.6 | 21.2 | 0.509 |
| Diuretic (%) | 64.3 | 51.5 | 0.033 |
|  |  |  |  |
| **Laboratory** |  |  |  |
| Glucose (mg/dL) | 104 ± 8.6 | 109 ± 8.6 | 0.357 |
| Uric acid (mg/dL) | 6.0 ± 1.5 | 6.1 ± 1.4 | 0.478 |
| Hb (g/L) | 13.7 ± 1.3 | 13.7 ± 1.3 | 0.46 |
| Ht (%) | 41.7 ± 3.4 | 41.4 ± 3.9 | 0.393 |
| Creatinine (mg/dL) | 1.06 ± 0.25 | 1.04 ± 0.21 | 0.406 |
| Urea (mg/dL) | 47.7 ± 16.4 | 39.8 ± 16.2 | 0.086 |
| Total cholesterol (mg/dL) | 175 ± 42.2 | 166 ± 31.9 | 0.25 |
| HDL cholesterol (mg/dL) | 44 ± 8.7 | 48 ± 11.8 | 0.113 |
| LDL cholesterol (mg/dL) | 102 ± 38.9 | 94 ± 20.7 | 0.222 |
| Triglycerides (mg/dL) | 141 ± 82.0 | 116 ± 32.9 | 0.102 |
|  |  |  |  |
| **Tonometry** |  |  |  |
| Heart rate (beats/min) | 67.3 ± 14.8 | 76.5 ± 17.0 | 0.013 |
| bSBP (mmHg) | 145.0 ± 29.6 | 137.9 ± 22.5 | 0.143 |
| bDBP (mmHg) | 77.8 ± 13.3 | 81.0 ± 14.6 | 0.18 |
| bPP (mmHg) | 67.1 ± 23.7 | 56.9 ± 17.7 | 0.027 |
| bMAP (mmHg) | 100.3 ± 16.9 | 100.0 ± 15.6 | 0.476 |
| cSBP (mmHg) | 136.2 ± 26.5 | 134.0 ± 20.2 | 0.352 |
| cDBP (mmHg) | 84.3 ± 13.7 | 89.5 ± 15.2 | 0.083 |
| cPP (mmHg) | 51.9 ± 21.5 | 44.4 ± 17.1 | 0.065 |
| cMAP (mmHg) | 104.4 ± 17.4 | 108.5 ± 16.8 | 0.177 |
| cfPWV (m/s) | 11.1 ± 3.3 | 10.1 ± 3.0 | 0.116 |
| Adj cfPWV, m/s (\*) | 11.0 ± 0.5 | 10.2 ± 0.5 | 0.313 |
| Aix 75, % | 26.7 ± 15.2 | 29.8 ± 17.4 | 0.224 |
| Adj Aix 75, % (\*) | 25.9 ± 2.8 | 30.6 ± 2.7 | 0.238 |
| Aortic augmentation (AP) (mmHg) | 17.1 ± 12.6 | 14.5 ± 13.8 | 0.227 |
| Period HR (ms) | 940 ± 236 | 829 ± 226 | 0.032 |
| Ejection duration (ms) | 303 ± 44.8 | 295 ± 47.3 | 0.257 |
| Ejection duration (%) | 33.2 | 36.9 | 0.013 |
| Aortic T2 (ms) | 210 ± 23.8 | 208 ± 28.3 | 0.362 |
| P1 height (mmHg) | 39.8 ± 15.5 | 34.0 ± 11.5 | 0.048 |
| PTI systole (mmHg) | 2446 ± 621 | 2731 ± 778 | 0.058 |
| PTI diastole (mmHg) | 3819 ± 595 | 3779 ± 454 | 0.382 |
| End systolic pressure (mmHg) | 124.9 ± 22.6 | 125.1 ± 19.1 | 0.483 |

(\*): ± SE; b:brachial; c: central; SBP: systolic blood pressure; DBP: diastolic blood pressure;

PP: pulse pressure; MAP: mean arterial pressure; cfPWV: carotid-femoral pulse wave velocity;

Adj: adjusted carotid-femoral pulse wave velocity adjusted by bMAP: gender: and age;

Aix 75: augmentation index normalized for a heart rate of 75 bpm; Aortic T2: duration from the start of

the pulse to the 2nd systolic peak; P1 height: primary wave pressure at T1; PTI: the area under the pressure pulse during systole and diastole; CCB: calcium-channel blocker; BB: beta-blocker (Atenolol); ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; HB: hemoglobin; Ht: hematocrit; HDL: high-density lipoprotein; LDL: low-density lipoprotein.